GNAS-AS1: A Protein Implicated in Various Diseases (G149775)

Target Name: GNAS-AS1

NCBI ID: G149775

GNAS-AS1

GNAS-AS1: A Protein Implicated in Various Diseases

GNAS-AS1 (Guanosine adenylate binding protein-AS1) is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell signaling pathways, and its dysfunction has been implicated in numerous diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a drug target and biomarker, GNAS-AS1 has significant potential for the development of new therapeutic approaches.

GNAS-AS1 functions as a guanosine analogase, which converts guanosine to guanosine monophosphate (GMP) in a process that regulates protein-protein interactions and cell signaling pathways. GNAS-AS1 is a critical regulator of the negative signaling pathway, which is involved in the regulation of cell proliferation, apoptosis, and inflammation. In this pathway, GNAS-AS1 plays a vital role in the negative regulation of the microtubule dynamics, which is essential for the proper cell division and apoptosis.

GNAS-AS1 has been shown to be involved in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, GNAS-AS1 has been implicated in the development and progression of neurobladder cancer. Studies have shown that GNAS-AS1 expression is increased in neurobladder cancer tissues compared to normal tissues, and that inhibition of GNAS-AS1 has led to a significant reduction in neurobladder cancer cell proliferation.

Another study has shown that GNAS-AS1 is involved in the development of Alzheimer's disease. The study found that GNAS-AS1 was expressed in the brains of individuals with Alzheimer's disease, and that overexpression of GNAS-AS1 was associated with the development of neuropathological changes in these individuals. Therefore, GNAS-AS1 may be a potential drug target for the treatment of Alzheimer's disease.

In addition to its involvement in neurodegenerative diseases, GNAS-AS1 has also been implicated in the development and progression of cancer. For example, GNAS-AS1 has been shown to be involved in the development and progression of colorectal cancer. Studies have shown that GNAS -AS1 expression is increased in colorectal cancer tissues compared to normal tissues, and that inhibition of GNAS-AS1 has led to a significant reduction in colorectal cancer cell proliferation.

Furthermore, GNAS-AS1 has also been shown to be involved in the development and progression of other diseases, including cardiovascular diseases and autoimmune diseases. For example, GNAS-AS1 has been implicated in the development and progression of heart failure. Studies have shown that GNAS-AS1 expression is increased in heart failure tissues compared to normal tissues, and that inhibition of GNAS-AS1 has led to a significant reduction in heart failure cell proliferation.

In conclusion, GNAS-AS1 is a protein that is involved in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a drug target and biomarker, GNAS-AS1 has significant potential for the development of new therapeutic approaches. Further research is needed to fully understand the role of GNAS-AS1 in disease progression and to develop effective treatments.

Protein Name: GNAS Antisense RNA 1

The "GNAS-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GNAS-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets